AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CLEVELAND, Feb. 15, 2018 --
|
|||||
Parker Hannifin Corporation, the global leader in motion and control technologies, today announced that the U.S. Food and Drug Administration (FDA) has given additional clearance to market and sell the Indego exoskeleton for use in the treatment of individuals with hemiplegia due to stroke. By expanding on its original clearance for individuals with a spinal cord injury, this announcement makes Indego the most broadly available exoskeleton for gait therapy and personal use in the United States.
“We are excited that Indego is now available for a much larger number of patients in the United States, enabling stroke patients to have access to this novel gait therapy,” said Achilleas Dorotheou, head of the human motion and control business unit for Parker.
The American Heart Association estimates that 795,000 Americans suffer a stroke every year and report that stroke is the leading cause of long-term disability in the country. Assistance with ambulation in a clinical environment may aid in the recovery of gait impairments, which is one of the most desired goals for stroke survivors undergoing rehabilitation.
The recent FDA clearance came after the completion of a large, multi-site clinical trial involving eight rehabilitation centers in the U.S., where a broad range of stroke patients received gait therapy with Indego and its therapy software suite.
“With the Therapy+ Software Suite, Indego can be used to provide individualized and patient-centric training, which is of critical importance for successful gait therapy sessions with stroke patients,” said Dr. Karen Nolan from the Kessler Foundation, one of the clinical trial centers.
About Indego
Indego is a state-of-the-art rehabilitation and assistive technology designed to improve patient mobility and independence while offering clinicians a meaningful therapy tool. Indego has received FDA Clearance and CE Mark, allowing it to be sold commercially in the U.S. and Europe. Indego has also earned a UL Mark which was obtained through extensive testing to certify the high standards of the Indego system design, function, and safety. To learn more about Indego visit www.indego.com
About Parker Hannifin
Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.
###
Media – Aidan Gormley, Director, Global Communications and Branding 216/896-3258 [email protected]
